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dose volume constraints, TCP and NTCP parameters were 
used for optimization of rotational IMRT treatment plans. 
Materials and Methods: We selected 28 patients with high-
risk localised prostate cancer and 2 out of 3 risk factors (PSA 
≥ 20ng/ml, dominant Gleason 4 or 5, T3a or T4 stage on MRI), 
or one risk factor and a bulky DIL (> 5mm diameter) on the 
staging MRI scan. Functional MRI's were used to define boost 
volumes with a margin of 5 mm to define the boost PTV. Neo-
adjuvant hormone therapy was given for 3 months before 
radiotherapy with fiducial markers, bowel and bladder 
preparation and daily IGRT. 
Results: Mean age was 66 years, mean PSA was 17.4 ng/ml 
(range 4.6-59.1), 20 patients had T3a and 10 had Gleason 
score ≥ 8. The mean dose to the prostate excluding the boost 
volume was 61.4 Gy (range 60.6-62.3) and the boost PTV 66.1 
Gy (range 60.9-72.5). Mean NTCP for rectal bleeding was 4.7% 
(range 3.4-5.8), for faecal incontinence 3.5% (range 2.3-5) 
and mean TCP 75% (range 71-79) assuming a 71% biochemical 
control at 5 years for a standard plan. All patients completed 
radiotherapy, 16/28 patients had acute bladder toxicity 
grade 2 (RTOG score), but no grade 3 toxicity was observed. 
Worst acute bowel toxicity was grade 1 (4/28). Mean follow 
up was 15 months (range 8-25). For the 20 patients who had 
neo-adjuvant hormone therapy beyond 6months, the mean 
PSA was 0.33 ng/ml (range 0.2-0.8), 2 patients had relapsed 
at 12 month with PSA only (PSA= 3.46) and bone metastasis 
(PSA=9.16 ng/ml), 6 patients are still on hormone therapy at 
2-3 years. Four patients had Grade 2 urinary late toxicities 
(CTCv4, 1 bladder neck necrosis, 1 urethral stricture post 
TURP, 2 urinary frequency). Two patients developed grade 1 
diarrhoea. Patient reported outcomes >6 month after 
completion of radiotherapy (EPIC QOL questionnaire) 
demonstrated similar scores to controls without prostate 
cancer for the bowel domains; reduction in the urinary 
domains was similar but no worse than other cohorts treated 
with external beam radiotherapy and hormone therapy. 
Conclusions: In this high risk group, dose escalation with 
hypo-fractionated dose painting radiotherapy achieved good 
biochemical control and urinary and bowel toxicity similar to 
standard dose radiotherapy during follow up. 
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Purpose/Objective: Separated arc VMAT (Sep) may have 
advantage over single continuous arc VMAT (Sng), because we 
can select gantry angle ranges with collimation angles 
properly according to the anatomical situations. In this study 
we compared dosimetric, volumetric and dose delivering 
parameters between Sep and Sng in the prone position, and 
we revealed linear relationships between these parameters 
and rectal override volume (ROV) on the PTV. As a result, 
Sep need lesser time and MU than Sng in the wide range 
clinical situations to achieve equal dosimetric and volumetric 
upshot.  
Materials and Methods: Forty cases were selected from our 
database who were treated prostate carcinoma in the feet-
first prone position. Gantry angle ranges and collimation 
angles (indicated in parentheses) of Sep were 182 - 230 
(280), 276 - 348 (10), 12 - 84 (350) and 130 - 178 (260). Those 
of Sng were 182 - 178 (0). Using SmartArc system of 
Pinnacle3 we calculated plans in combination with a 6MVX 
physical data of Novalis Tx. We used the same consolidations 
for optimization. For example, Min Dose, D95 and Max Dose 
of PTV were 76 Gy, 80 Gy and 84 Gy, respectively. Rectal V40 
was 20%. Wilcoxon rank sum test was applied to D98, D95, 
D50 and D02 of PTV, rectal V40, irradiation time and MU. 
These were gained from Sng 90 control points plan calculated 
with a gap of 4 degrees or Sep 99 control points plan 
calculated with a gap of 2 degrees. To analyse relationships 
between these values and ROV, linear regression model was 
employed. Homogeneity of slopes was checked by in-house R 
script. 
Results: Mean values of D98, D95, D50 and D02, V40, Time 
and MU were 75.6 Gy, 77.4 Gy, 81.2 Gy, 84.5Gy, 20.1%, 82.9 
sec and 652.3 for Sng ,and were 75.4 Gy, 77.3 Gy, 81.0 Gy, 
84.2 Gy, 20.6 %, 66.7 sec and 594.4 for Sep, respectively. 




D02, V40, Time and MU depended on ROV significantly in the 
both Sng and Sep plans. Slopes were very similar in the all 
parameters. Intercepts of Time and MU of Sng and Sep were 
different largely. 




Conclusions: Sng and Sep plans were very similar from the 
dosimetric (D98, D95, D50, D02) and volumetric (V40) point 
of view. However, in terms of dose delivery (Time, MU), 
differences were remarkable. This may ecologically 
profitable and save patient times. These differences were 
unfluctuating, even if the ROV were changed broadly in the 
clinical situation. 
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Purpose/Objective: To report toxicity considering overall 
treatment time of intensity Modulated Arc Therapy (IMAT) 
with simultaneous integrated boost (SIB) for patients with 
intermediate or high-risk prostate cancer.  
Materials and Methods: One hundred forty two consecutive 
patients, diagnosed with intermediate or high risk prostate 
cancer, were treated definitively between September 2011 
and May 2014. Androgen suppression was administered 
considering disease risk factors. The IMAT plans were 
designed to deliver 70.8 Gy in 30 fractions (2.36 Gy/fraction) 
while delivering simultaneously to the prostate plus margin 
60 Gy (2Gy/fraction).Univariate and multivariate analysis 
with logistic regression were performed looking for relations 
among patient characteristics and toxicity. CTCAE v3.0 
morbidity scores were used to assess acute and late 
toxicities. Outcome, measurements: toxicity and biochemical 
response were assessed prospectively. 
Results: Median age of those patients was 72 years old (from 
58 to 81). Pathologically centralized Gleason score was 7 for 
81.7 % of patients. Mean PSA value was 9.6 ng/ml (from 2 to 
36ng/ml). Forty one percent of patients were classified as 
T1-T2a, 37.5% as T2b-c and 21.5% as T3. Median IPPS was 5 (0 
to15). The median follow-up period was 14.8 months. All 
patients received the prescribed dose in 30 fractions 
delivered between 36 to 57days. Median radiation overall 
treatment time (OTT) was 47 days. Seventy-five percent of 
patients received a course of hormone deprivation for 6 
months at least. One biochemical relapse was observed in 
this cohort of patients. Five patients died during the follow-
up period without cancer relapse or toxicity. Acute genito-
urinary toxicity was observed in 81% of patients with maximal 
score of 2 in 40.9% of patients. Rectal acute toxicity grade 2 
with mucosal discharge was present in 17.6%. Presence of any 
acute rectal toxicity risk is increased by 2.3 fold in the 
shorter OTT. Late rectal toxicity Grade 3 was seen in one 
patient and 5 more patients showed grade 2 score. Chronic 
urinary toxicity grades 1-2 were observed in 27.5% of 
patients, but only two patients with grade 2. Absence of 
acute toxicities decreased the risk for chronic rectal toxicity 
by 0.2 and urinary by 0.09. Neither, hormonal deprivation nor 
fiducial markers for IGRT showed any impact on toxicity. 
Presence of any acute rectal toxicity risk is increased by 2.3 
fold in the shorter OTT. Initial IPSS increased 1.2 fold the risk 
to present any grade of late the urinary toxicity.  
Conclusions: IMAT with SIB to the prostate was well 
tolerated in this series, with acceptable rates of acute and 
early late toxicity. Shorter OTT seems to increase the risk of 
acute rectal toxicity whereas initial IPSS increased the risk of 
late urinary toxicity. The absence of both acute rectal and 
urinary toxicities decreased the risk of chronic toxicities. 
Additional follow-up is necessary to fully define the long-
term toxicity.  
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Purpose/Objective: We initiated a correlative analysis of 
urinary toxicity (UT) and radiation-induced lymphopenia to 
test the hypothesis that patients (pts) experiencing more 
severe lymphopenia may be at higher risk for UT, owing to 
